Clinical trials: CYP19
Cognitive Side Effects of Cancer Therapy, Hypoestrogenism
ENDO-BRAIN: Effects of Endocrine Adjuvant Therapy with Aromatase Inhibitors on the Cognitive Function of Breast Cancer Patients
The principal aim of this prospective observational study is to investigate the cognitive function of breast cancer patients that use AI, comparing it with age-matched healthy controls, utilizing cognitive assessments and…
- Trial name
- ENDO-BRAIN (NCT06606535)
- Testing
- validated questionnaires, functional MRI, Optical Coherent Tomography Angiography
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ospedale Policlinico San Martino
Breast Cancer
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
The purpose of the study was to evaluate the safety and efficacy of a reduced ribociclib starting dose of 400 mg in combination with a non-steroidal aromatase inhibitor (NSAI) (letrozole or anastrozole) for the treatment of pre…
- Trial name
- AMALEE (NCT03822468)
- Testing
- Ribociclib, Anastrozole, Letrozole
- Where
- 89 sites in United States, Argentina and 21 more
- Volunteers
- 376 people
- Sponsor
- Novartis Pharmaceuticals
Vasomotor Symptoms
Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms
Breast cancer is the most prevalent cancer type worldwide. In Egypt, It is the second most common type of cancer and the most common one in women with about 22 thousand new cases in 2020.
- Trial name
- NCT05637671
- Testing
- oxybutynin ER, Paroxetine CR
- Where
- Egypt
- Volunteers
- 146 people
- Sponsor
- Cairo University
Male Breast Cancer, Recurrent Breast Cancer
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01153672
- Testing
- vorinostat, laboratory biomarker analysis, biopsy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
Breast Cancer
Coagulation Parameters in Postmenopausal Breast Cancer Patients Under Adjuvant Hormonal Therapy
The objective of the study is to monitor the changes of blood coagulation parameters in postmenopausal patients who are treated with adjuvant Hormonal Therapy for a total of 5 years.
- Trial name
- COPA (NCT00814034)
- Where
- 2 sites in Greece
- Volunteers
- 306 people
- Sponsor
- Hellenic Breast Surgeons Society
Symptomatic or Large Uterine Fibroids
Aromatase Inhibitors for Treatment of Uterine Leiomyomas
Fibroids are benign tumors that might results in bleeding. Surgery is their definitive treatment. Some medical therapies have been tried for women who wish to preserve their uterus.
- Trial name
- NCT00945360
- Testing
- Letrozole (aromatase inhibitor)
- Where
- Lebanon
- Sponsor
- American University of Beirut Medical Center
Joint Pain, Breast Cancer
Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy
For post-menopausal women diagnosed with hormone-receptor positive breast cancer tumors, aromatase inhibitors (AIs) are the standard adjuvant hormone treatment to prolong disease-free survival and time-to-recurrence.
- Trial name
- NCT01900418
- Testing
- Walk with Ease
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- University of North Carolina, Chapel Hill
Endometrial Carcinoma
Letrozole as a Treatment of Endometrial Cancer
Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole blocks estrogen production in the body. The purpose of this study is to determine if the investigators can predict which patients might…
- Trial name
- NCT00997373
- Testing
- Letrozole
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of California, Davis
Breast Cancer
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).
- Trial name
- FINER (NCT04650581)
- Testing
- Ipatasertib, Fulvestrant
- Where
- 39 sites in Australia, Canada and 1 more
- Volunteers
- 250 people
- Sponsor
- Canadian Cancer Trials Group
Hot Flushes, Hot Flashes
Stellate Ganglion Block (SGB) For Women for Breast Cancer
Vasomotor symptoms (VMS) affect up to 65% of breast cancer survivors and negatively impact their quality of life. The investigators aim to evaluate the benefit of SGB in symptomatic women with breast cancer who are on…
- Trial name
- NCT02513329
- Testing
- Bupivicaine, Saline
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Northwestern University
Vaginal Atrophy in Breast Cancer Patients
Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer
The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on moderate to severe (MS) and most bothersome symptoms (MBS) of vulvovaginal atrophy (VVA) due to natural, surgical or treatment-induced…
- Trial name
- NCT03740945
- Testing
- Prasterone (DHEA)
- Sponsor
- EndoCeutics Inc.
Breast Cancer
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
The primary objective of Phase 1b will be to evaluate the safety and tolerability of TTI-101 when added to palbociclib and AI or fulvestrant administered orally to participants with hormone receptor-positive (HR+) human epidermal…
- Trial name
- NCT05384119
- Testing
- TTI-101, Palbociclib, Aromatase inhibitor (AI)
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Breast Cancer
Fasting-mimicking Diet Intervention on Side Effects of Aromatase Inhibitors Treatment in Patients With Breast Cancer
The primary endpoint of this study is to determine whether cycles of short term FMD exposure to a fasting-mimicking diet is effective in reducing total cholesterol levels.
- Trial name
- NCT06610565
- Testing
- FASTING-MIMICKING DIET PROGRAM
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- European Institute of Oncology
Breast Cancer Females
Short-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer
Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. While there is a clear linear relationship between the duration of aromatase inhibitor use and the cumulative incidence of…
- Trial name
- STRIVE (Acute) (NCT06781762)
- Testing
- N/A (Usual Care)
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Anxiety Disorder, Breast Cancer
Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Acupuncture may help relieve muscle and bone pain caused by aromatase inhibitor therapy, such as letrozole, exemestane, and anastrozole.
- Conditions
- Anxiety Disorder, Breast Cancer, Depression, Fatigue
- Trial name
- NCT00641303
- Testing
- acupuncture therapy
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- University of Maryland, Baltimore
Breast Neoplasms, Neoplasms, Hormone-Dependent
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another…
- Trial name
- NCT00097344
- Testing
- Atamestane, Toremifene, Letrozole
- Where
- 104 sites in United States, Bulgaria and 3 more
- Volunteers
- 842 people
- Sponsor
- Intarcia Therapeutics
Breast Neoplasms
Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients
To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)
- Trial name
- NCT00174343
- Testing
- exemestane (Aromasin®)
- Where
- 5 sites in France
- Volunteers
- 46 people
- Sponsor
- Pfizer
Male Breast Cancer, Recurrent Breast Cancer
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving hormone therapy. Vorinostat may help hormone therapy work better by making tumor cells more sensitive to the drug.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01720602
- Testing
- vorinostat, anastrozole, letrozole
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Washington
Locally Advanced Breast Cancer, Metastatic Breast Cancer
A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.
70% of breast cancers that occur in postmenopausal women rely on the hormone oestrogen to grow and are likely to respond to hormone treatment.
- Trial name
- IRIS (NCT01785992)
- Testing
- Irosustat
- Where
- 9 sites in United Kingdom
- Volunteers
- 27 people
- Sponsor
- Imperial College London
Reproductive Behavior
Endometrial Preparation in Frozen Embryo Transfer Cycles
Comparison of protocols for frozen embryo transfer (ET): One protocol using Estrogen supplements and the second protocol using Letrozole
- Trial name
- NCT03540979
- Testing
- endometrial preparation for frozen blastocyst transfer, Letrozole, Ovidrel
- Volunteers
- 100 people
- Sponsor
- Meir Medical Center